比较候选地舒单抗生物类似药RGB-14-P与参照地舒单抗在绝经后骨质疏松女性中疗效与安全性的随机3期研究
这项多中心、双盲、3期研究将473例绝经后骨质疏松女性随机分配接受RGB-14-P或地舒单抗60 mg皮下注射,每6个月一次。第52周腰椎骨密度变化百分比及至第26周血清CTX变化百分比的有效曲线下面积两项主要终点均显示等效。免疫原性和安全性相似。
要点
- RGB-14-P与地舒单抗在腰椎骨密度变化百分比和CTX有效曲线下面积上达到等效。
- 两组抗药抗体发生率均低于1%,安全性和免疫原性相似。
- 地舒单抗生物类似药RGB-14有潜力以相当疗效和安全性提供更低成本的选择。
核心结论
- 在绝经后骨质疏松女性中,RGB-14-P的疗效和药效学与地舒单抗等效,免疫原性和安全性相似。
研究设计与样本
- 多中心、双盲、3期研究(EudraCT 2020-006017-38;NCT05087030),473例参与者随机1:1接受皮下RGB-14-P或地舒单抗60 mg,每6个月一次,第1天和第26周给药,随访至第52周。
主要发现
- 第52周腰椎骨密度变化百分比的校正均值(95%CI)为RGB-14-P组4.89(3.55, 6.24)vs 地舒单抗组4.55(3.22, 5.87),估计差异0.34(95%CI -0.40, 1.09)。
- 至第26周血清CTX变化百分比的有效曲线下面积的几何均值比为1.01(95%CI 0.98, 1.05;P=0.494)。
- 全髋和股骨颈骨密度变化百分比两组间无统计学差异,椎体或非椎体脆性骨折发生率相当。
- 两组抗药抗体发生率均低于1%,安全性相当。
关键数值与推荐
- 主要终点为第52周腰椎骨密度变化百分比和至第26周血清CTX变化百分比的有效曲线下面积。
- RGB-14-P组n=242,地舒单抗组n=231。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: • In women with postmenopausal osteoporosis, proposed denosumab biosimilar RGB-14-P demonstrated equivalent efficacy and pharmacodynamics, and similar immunogenicity and safety to reference denosumab. • RGB-14-P comprehensively replicates the therapeutic benefit of denosumab in a clinical setting. • Denosumab biosimilars, such as RGB-14, have potential to provide lower-cost alternatives to denosumab with comparable efficacy and safety. PURPOSE: To demonstrate the equivalence of the proposed denosumab biosimilar RGB-14-P and the reference denosumab (hereafter denosumab) in women with postmenopausal osteoporosis. METHODS: In this multicentre, double-blind, Phase 3 study (EudraCT 2020-006017-38; NCT05087030), participants were randomised 1:1 to subcutaneous RGB-14-P or denosumab 60 mg every 6 months, on Day 1 and Week 26, with follow-up to Week 52. Primary endpoints were percentage change from baseline (%CfB) in lumbar spine bone mineral density (BMD) at Week 52 and area under the effective curve (AUEC) of %CfB serum C-terminal telopeptide of type 1 collagen (CTX) to Week 26. Secondary endpoints included %CfB in total hip and femoral neck BMD, vertebral and non-vertebral fragility fractures, immunogenicity, and safety to Week 52. RESULTS: Overall, 473 participants were randomised and received study drug (RGB-14-P, n = 242; denosumab, n = 231). Both primary endpoints demonstrated equivalence of RGB-14-P and denosumab. Adjusted mean (95% CI) %CfB in lumbar spine BMD at Week 52 was 4.89 (3.55, 6.24) for RGB-14-P and 4.55 (3.22, 5.87) for denosumab (estimated difference, 0.34; 95% CI, - 0.40, 1.09). Geometric mean ratio in AUEC of %CfB in CTX concentration was 1.01 (95% CI, 0.98, 1.05; P = 0.494). There were no statistical differences in %CfB in total hip and femoral neck BMD. Incidence of vertebral or non-vertebral fragility fractures was comparable between treatments. Anti-drug antibody incidence was < 1% in both arms. Safety was comparable between groups. CONCLUSION: In women with postmenopausal osteoporosis, RGB-14-P demonstrated equivalent efficacy and pharmacodynamics, and similar immunogenicity and safety to denosumab.
引用
- Seefried L, Ferrari S, Páll D, et al. A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis. Osteoporos Int. 2025. PMID: 41085683. doi:10.1007/s00198-025-07711-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。